PhD, 2008, University of Southern California, Los Angeles, CA
MS, 2001, University of Southern California, Los Angeles, CA
MS, 1998, Peking University, Beijing, China
BS, 1995, Peking University, Beijing, China
|
|
|
|
Courses Taught:
|
BIOS 520: Clinical Trials
|
|
|
|
Career Overview:
|
- Designs and some critical issues of Phase I, II, and III clinical trials
- Dose-Toxicity Bayesian models in cancer Phase I clinical trials
- A novel toxicity score system to measure the multiple toxicities per patient quantitatively and comprehensively in Phase I clinical trials
- Methods treating disease response as a continuous variable instead of using RECIST in Phase II clinical trials
|
|
|
|
Selected Publications:
|
, Tighiouart M, Kowalski J.
Dose Escalation with Overdose Control using a Quasi-Continuous Toxicity Score in Cancer Phase I Clinical Trials
Contemporary Clinical Trials (In Press) , 2012.
|
|
|
, Krailo MD, Azen SP, Tighiouart M.
A Novel Toxicity Scoring System Treating Toxicity Response as a Quasi-Continuous Variable in Phase I Clinical Trials
Contemporary Clinical Trials , 31: 473-482, 2010.
|
|
|
, Krailo MD, Sun J, Azen SP
Range and trend of expected toxicity level (ETL) in standard A+B designs: A report from the children's oncology group
Contemporary Clinical Trials , 30(2): 123-8., 2009.
|
|
|
, Wu AH, Gauderman J, Bernstein L, Ma H, Pike MC, Ursin G.
Does mammographic density reflect ethnic differences in breast cancer incidence rates?
American Journal of Epidemiology , 159: 140-147, 2004.
|
|
|
, Ren L, Shao Q, Shi D, Ru B
Expression of mammalian metallothionein-I gene in cyanobacteria to enhance heavy metal resistance
Marine Pollution Bulletin , 39: 155-158, 1999.
|
|
|
, Li XF, Shi DJ, Ru B
Studies on the purification, characterization and conformation in solution of metallothionein-like substance from Synechocystis 6803
Acta Botanica Sinica , 41(2): 150-155, 1999.
|
|
|
|
Other affiliations and Activities:
|
|
SOFTWARE DEVELOPED
1. ID-NETS (Isotonic Design using Normalized Equivalence Toxicity Score).
ID-NETS is a novel Phase I design, which has substantially improved the accuracy of maximum tolerated dose (MTD) estimation and efficiency of trial by fully utilizing all toxicities of each patient and treating toxicity response as a quasi-continuous variable instead of a binary indicator of dose limiting toxicity (DLT) in a Phase I clinical trial.
ID-NETS is available for free download at website below: http://winshipbbisr.emory.edu/Software.html
2. EWOC-NETS (Escalation with Overdose Control using Normalized Equivalence Toxicity Score).
EWOC-NETS is a novel Bayesian adaptive design which is a combination of EWOC and our NETS system. EWOC-NETS can not only retain all the advantages of EWOC, but also treat toxicity response as a quasi-continuous variable, fully utilize all toxicity information, and improve the accuracy of MTD and efficiency of Phase I trial.
EWOC-NETS will be available for free download at website below: http://winshipbbisr.emory.edu/Software.html
|
|
|
|
Curriculum Vitae
|
|
|
|
Link to this page: http://www.sph.emory.edu/faculty/ZCHEN38
|
|
|
